US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Ascletis Pharma Inc.

2.10

+0.12006.06%

Volume:500.00

Turnover:1.05K

Market Cap:2.05B

PE:-51.02

High:2.10

Open:2.10

Low:2.10

Close:1.98

52wk High:2.29

52wk Low:0.6217

Shares:976.78M

Float Shares:145.50M

Volume Ratio:11.75

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0412

EPS(LYR):-0.0412

ROE:-12.77%

ROA:-12.32%

PB:7.59

PE(LYR):-51.02

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Ascletis Pharma Inc.

Exchange:

PINK LIMITED

Establishment Date:

2013

Employees:

208

Office Location:

12/F, Building D,198 Qidi Road, HIPARK,Xiaoshan District,Hangzhou,Zhejiang Province,China

Website:

- -

Zip Code:

311200

Phone:

86 571 8538 9730

Fax:

86 571 8538 9730

Introduction:

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB); ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ASCLF/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ASCLF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASCLF\",,,,,undefined,":{"symbol":"ASCLF","market":"US","secType":"STK","nameCN":"Ascletis Pharma Inc.","latestPrice":2.1,"timestamp":1770733808413,"preClose":1.98,"halted":0,"volume":500,"delay":15,"changeRate":0.06060606060606066,"floatShares":145496269,"shares":976782000,"eps":-0.041164,"marketStatus":"Trading","change":0.12,"latestTime":"02-10 09:30:08 EST Delay","open":2.1,"high":2.1,"low":2.1,"amount":1050,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.041164,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770757200000},"marketStatusCode":2,"adr":0,"exchange":"PINK LIMITED","adjPreClose":1.98,"volumeRatio":11.74982},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASCLF\",,,,,undefined,":{"symbol":"ASCLF","floatShares":145496269,"roa":"-12.32%","roe":"-12.77%","lyrEps":-0.041164,"volumeRatio":11.74982,"shares":976782000,"dividePrice":0,"high":2.1,"amplitude":0,"preClose":1.98,"low":2.1,"week52Low":0.6217,"pbRate":"7.59","psRate":"5994.18","week52High":2.29,"institutionHeld":0,"latestPrice":2.1,"eps":-0.041164,"divideRate":0,"volume":500,"delay":15,"ttmEps":-0.041164,"open":2.1,"prevYearClose":1.485,"prevWeekClose":1.75,"prevMonthClose":1.75,"prevQuarterClose":1.485,"fiveDayClose":1.75,"twentyDayClose":1.53,"sixtyDayClose":1.145},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ASCLF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2022-08-22","symbol":"ASCLF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1661140800000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ASCLF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ASCLF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.75,"buy":0,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.75,"analysts":4,"updateTime":1749704400000},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":574413177,"yearFounded":2013,"employeeNum":208,"address":"12/F, Building D,198 Qidi Road, HIPARK,Xiaoshan District,Hangzhou,Zhejiang Province,China","zipCode":"311200","officePhone":"86 571 8538 9730","officeFax":"86 571 8538 9730"},"stockCompanyDetail":{"description":"Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB); ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.","exchange":"PINK LIMITED","name":"Ascletis Pharma Inc.","nameEN":"Ascletis Pharma Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ASCLF\",market:\"US\",,,undefined,":null}}